All News

Top news of the day from across the health care landscape.

Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).

The report highlighted the reasoning for the drug shortage as well as specific applicants and manufacturers that the agency will be working with to mitigate the supply of Ig products.

Along with her B.S. in pharmacy from UNC-Chapel Hill, author Amy Greeson’s education has included some much more unique experiences. She’s been to Belize to study native therapies, studied in the Amazon with a local medicine man and woman, and learned from traditional healers in Mexico.

The FDA has given the green light to rituximab (Rituxan) injection for the treatment of granulomatosis with polyangiitus (GPA) and microscopic polyangiitis (MPA) in children age 2 and older in combination with glucocorticoids. The application was approved under priority review and with orphan designation.

Research discusses specific mindsets that could affect the health of patients with cancer: regarding the disease as either a catastrophe or an opportunity and seeing the body as either a friend or foe.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Wednesday was World Pharmacist Day, and pharmacists all around the world celebrated their profession. We asked why you were thankful to be a pharmacist and how you were celebrating, and you responded!

Ahead of World Heart Day, Amgen has released a study demonstrating that patient education is still necessary to combat cardiovascular disease.

Daratumumab was approved based on results from part one of the Phase III CASSIOPEIA study.

Patients with metastatic colorectal cancer harboring certain non-V600 BRAF mutations may benefit from anti-EGFR treatment.

Value assessment frameworks are expected to play a more pivotal role in decisions that affect future patient choice and access.

The vitamin D and omega-3 clinical trial (VITAL) is the largest, most recent study to test this subject matter, with nearly 26,000 United States men and women participating in the trial.

Study indicated that patients who received radiation 30 days or fewer before their CAR T-cell infusion did not experience serious cytokine release syndrome or neurotoxicity.

Mammography found more effective at detecting breast cancer in men with high risk than for women with an average risk and in detecting the disease before it metastasizes.

Top news of the day across the health care landscape.